Humacyte

Biotechnology ResearchNorth Carolina, United States51-200 Employees

Humacyte, a mid-sized biotechnology company based in Durham, North Carolina, operates in the regenerative medicine space. It develops acellular tissue constructs intended for broad patient compatibility and capable of remodeling with the recipient’s cells over time, effectively serving as replacement vessels. Its Acellular Tissue Engineered Vessel program has attracted regulatory designations and culminated in full FDA approval in December 2024 for extremity arterial trauma, after earlier designation such as RMAT for dialysis access and a DoD priority designation for extremity repair. The company is advancing the ATEV through clinical trials for arteriovenous access in hemodialysis and for peripheral arterial disease, with additional preclinical work in coronary bypass grafts, pediatric heart surgery, type 1 diabetes, and other tissue applications. Its products are intended for use by clinicians and patients in vascular and regenerative medicine, addressing severe arterial injuries and related surgical needs while expanding the potential tissue replacement options.

Sign up for free to view info

Email Format Employee directory